Exactly-what is next? Covid put a stop to most "routine" healthcare activity when it hit, including most (if not all) drug trials. And IPIX had active trials ongoing at that time. People weren't even getting "routine" surgeries. This Covid trial provided a path forward at a time when most other avenues were closed due to the pandemic. Even though the trial didn't meet primary endpoints, it was a big lift to show effect in the population of the study. Now IPIX has a drug that (still) has potential interest for Covid (and/or other possible viral uses) in addition to those other potentials which were sidelined previously. I'm still holding and waiting on the final analysis and future developments.